Suppr超能文献

羟氯喹血药浓度在系统性红斑狼疮中的变化决定因素。

Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.

机构信息

Université Paris-Descartes, AP-HP, Hôpital Cochin, and Centre de Référence Maladies Auto-Immunes et Systémiques Rares, Paris, France.

Université Paris Diderot, Sorbonne Paris Cité, and AP-HP, Hôpital Saint Louis, Paris, France.

出版信息

Arthritis Rheumatol. 2015 May;67(8):2176-84. doi: 10.1002/art.39194.

Abstract

OBJECTIVE

Blood concentrations of hydroxychloroquine (HCQ) vary widely among patients with systemic lupus erythematosus (SLE). A pharmacokinetic/pharmacodynamic relationship has been found in different situations, and a very low blood concentration of HCQ is a simple marker of nonadherence to treatment. Therefore, interest in blood HCQ concentration measurement has increased, but little is known about factors that influence blood HCQ concentration variability. This study was undertaken to analyze determinants of blood HCQ concentrations.

METHODS

We conducted a retrospective analysis of patient data, including data from the Plaquenil Lupus Systemic (PLUS) study, to determine the association of epidemiologic, clinical, and biologic factors with blood HCQ concentrations. Data for nonadherent patients (blood HCQ concentration <200 ng/ml) were excluded.

RESULTS

To examine homogeneous pharmacologic data, we restricted the analyses of the PLUS data to the 509 SLE patients receiving 400 mg/day. We found no association of ethnicity or smoking with blood HCQ concentrations and no pharmacokinetic drug-drug interaction with antacids or with inhibitors or inducers of cytochrome P450 enzymes. On multivariate analysis, high body mass index (P = 0.008), no treatment with corticosteroids (P = 0.04), increased time between the last tablet intake and measurement of blood HCQ concentrations (P = 0.017), low platelet count (P < 0.001), low neutrophil count (P < 0.001), and high estimated creatinine clearance (P < 0.001) were associated with low blood HCQ concentrations. In 22 SLE patients with chronic renal insufficiency (median serum creatinine clearance 52 ml/minute [range 23-58 ml/minute]) who received 400 mg/day HCQ, the median blood HCQ concentration was significantly higher than that in the 509 patients from the PLUS study (1,338 ng/ml [range 504-2,229 ng/ml] versus 917 ng/ml [range 208-3316 ng/ml]) (P < 0.001).

CONCLUSION

We provide a comprehensive analysis of determinants of blood HCQ concentrations. Because this measurement is increasingly being used, these data might be useful for clinicians.

摘要

目的

系统性红斑狼疮(SLE)患者的羟氯喹(HCQ)血药浓度差异很大。在不同情况下已经发现了药代动力学/药效学关系,而 HCQ 的血药浓度非常低是治疗不依从的简单标志物。因此,人们对 HCQ 血药浓度检测的兴趣有所增加,但对影响 HCQ 血药浓度变异性的因素知之甚少。本研究旨在分析影响 HCQ 血药浓度的因素。

方法

我们对患者数据进行了回顾性分析,包括 Plaquenil Lupus Systemic(PLUS)研究的数据,以确定流行病学、临床和生物学因素与 HCQ 血药浓度的关系。排除不依从患者(HCQ 血药浓度<200ng/ml)的数据。

结果

为了检查同质的药效学数据,我们将 PLUS 数据的分析限制在 509 名接受 400mg/天治疗的 SLE 患者中。我们发现种族或吸烟与 HCQ 血药浓度无关,与抗酸剂或细胞色素 P450 酶抑制剂或诱导剂也无药代动力学药物相互作用。多变量分析显示,高体重指数(P=0.008)、不使用皮质类固醇(P=0.04)、末次服药与测量 HCQ 血药浓度之间的时间间隔延长(P=0.017)、血小板计数低(P<0.001)、中性粒细胞计数低(P<0.001)和估算的肌酐清除率高(P<0.001)与低 HCQ 血药浓度相关。在 22 名患有慢性肾功能不全(中位血清肌酐清除率 52ml/分钟[范围 23-58ml/分钟])的 SLE 患者中,接受 400mg/天 HCQ 治疗,其 HCQ 血药浓度中位数明显高于 PLUS 研究的 509 名患者(中位数为 1338ng/ml[范围 504-2229ng/ml]与 917ng/ml[范围 208-3316ng/ml])(P<0.001)。

结论

我们对影响 HCQ 血药浓度的因素进行了全面分析。由于这种测量方法的使用越来越多,这些数据可能对临床医生有用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验